3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Read more about 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Read more about Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
International cancer seminars: a focus on esophageal squamous cell carcinoma. Read more about International cancer seminars: a focus on esophageal squamous cell carcinoma.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Read more about Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Read more about Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Read more about Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Read more about Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Read more about Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Read more about Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Read more about Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
